Salim G Contractor, MD
Medical Oncology · Hudson
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · New York Oncology Hematology PC · 82 clinicians in this group
Hospitals listed: Albany Medical Center Hospital · Columbia Memorial Hospital · Samaritan Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Contractor’s office at (212) 459-8173 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Albany Medical Center HospitalAlbany, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Albany Medical Center, which runs 3 hospitalsPatients rate it 2 of 5 · 57% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.685, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.654, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.409, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.559, Oct 2024 – Sep 2025
- Columbia Memorial HospitalHudson, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Columbia Memorial HealthPatients rate it 2 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 2.17 (1.74 to 2.61), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 4.5 (3.5 to 5.5) · 1,825 cases, Jul 2022 – Jun 2024
- Samaritan Hospital of Troy, New YorkTroy, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 65% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.488, Oct 2024 – Sep 2025
See every measure and the patient survey for Albany Medical Center Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 10 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.685 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.654 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.409 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.559 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.42 (0.68 to 2.16) · 3,079 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.22 (1 to 1.44) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 202.26 (172.39 to 232.13) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 109 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.8 · 147 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 291 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.4 · 389 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 388 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 981 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 6,614 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.13 to 0.48) · 12,180 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.41 (0.23 to 0.58) · 12,734 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.05 (2.6 to 5.51) · 4,177 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.67 (1.34 to 4) · 1,570 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.53 (1.44 to 3.63) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.86 (6.3 to 15.41) · 1,447 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.28 (3.45 to 9.11) · 1,540 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.49 (0.2 to 2.77) · 905 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0.34 to 1.15) · 11,084 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5 · 33 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0.586 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.768 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.2 · 515 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 759 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 2.9 · 314 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11.5 · 436 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 8.5 · 378 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 554 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 6.7) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.3 (6.4 to 13.1) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.8 · 34 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 13 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 331 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (10 to 17) · 888 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 977 cases | No different | Jan 2024 – Dec 2024 |
What patients said (852 patients answered, 22% of those asked)
| Cleanliness | 1 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 56% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 79% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 54% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 33% |
| "YES", patients would definitely recommend the hospital | 57% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
See every measure and the patient survey for Columbia Memorial Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 5 the same, 1 worse of 6 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 2.17 (1.74 to 2.61) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 4.5 (3.5 to 5.5) · 1,825 cases | Worse | Jul 2022 – Jun 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0 to 2.01) · 220 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 12.7 · 93 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.6 · 153 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 162 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 53 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.8 · 1,035 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,041 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.13 to 0.55) · 1,988 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.91 (1.45 to 6.36) · 352 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.89 (1.19 to 4.59) · 331 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.1 (0 to 17.57) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.65 (2.46 to 10.85) · 163 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 75 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.692 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.676 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23.6 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 78.8 · 147 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.2 · 163 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 217 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.6 (3.5 to 9) · 37 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (6.5 to 14.9) · 37 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 23.5 · 208 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.4 (8.6 to 14.9) · 901 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 365 cases | No different | Jan 2024 – Dec 2024 |
What patients said (331 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 81% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
See every measure and the patient survey for Samaritan Hospital of Troy, New York
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 1 better, 8 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.488 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 694 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.56 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.74 (104.98 to 232.5) · 40 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 90 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 134 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.6 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.1 · 409 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 16.1 · 224 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.5 · 2,342 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 4,244 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.52) · 4,311 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.02 (0.73 to 5.31) · 663 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 177 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.21 (0.63 to 3.8) · 641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.31 (4.58 to 22.03) · 181 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.67 (0.57 to 8.77) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 188 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.98) · 3,627 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.792 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.81 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.505 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.529 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 220 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 650 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -15.6 · 113 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.5 · 368 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.1 · 417 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 622 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.6 to 8.1) · 73 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (8.7 to 16.2) · 73 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 17.6 · 260 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.7 to 16.1) · 1,868 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 276 cases | No different | Jan 2024 – Dec 2024 |
What patients said (506 patients answered, 19% of those asked)
| Cleanliness | 1 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 55% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 65% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 65% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$2,756,237
Medicare paid this office $2,756,237 for 776 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 13 | $661,365 | None |
| Return visit (30+ min) | 392 | $78,123 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 39 | $61,043 | $1,387 |
| Injection, denosumab, 1 mg | 11 | $43,110 | None |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $37,592 | $111 |
See all 63 services
| Injection, pembrolizumab, 1 mg | 13 | $661,365 | None |
| Return visit (30+ min) | 392 | $78,123 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 39 | $61,043 | $1,387 |
| Injection, denosumab, 1 mg | 11 | $43,110 | None |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $37,592 | $111 |
| Short return visit (20+ min) | 227 | $20,392 | $68 |
| Blood test, comprehensive group of blood chemicals | 661 | $19,261 | $10 |
| Insertion of needle into vein for collection of blood sample | 664 | $18,411 | $9 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 39 | $17,808 | $396 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 663 | $15,436 | $8 |
| New patient visit (45+ min) | 89 | $11,286 | $127 |
| Measurement of substance using immunoassay technique | 199 | $11,272 | $17 |
| Ferritin (blood protein) level | 330 | $9,821 | $13 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $9,450 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 48 | $9,228 | $52 |
| Gammaglobulin (immune system protein) measurement | 157 | $7,245 | $9 |
| Blood test, thyroid stimulating hormone (tsh) | 243 | $6,966 | $16 |
| Cyanocobalamin (vitamin b-12) level | 253 | $6,635 | $15 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13 | $5,743 | $0 |
| Folic acid level, serum | 219 | $5,418 | $14 |
| Iron binding capacity | 303 | $5,365 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $5,014 | $23 |
| Beta-2 microglobulin (protein) level | 192 | $5,012 | $16 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $4,709 | $55 |
| Injection of additional new drug or substance into vein | 50 | $4,629 | $13 |
| Lactate dehydrogenase (enzyme) level | 355 | $4,570 | $6 |
| Psa (prostate specific antigen) measurement, total | 128 | $4,109 | $18 |
| Iron level | 309 | $4,064 | $6 |
| New patient visit (60+ min) | 21 | $3,758 | $179 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,027 | $47 |
| Carcinoembryonic antigen (cea) protein level | 91 | $2,898 | $19 |
| Administration of chemotherapy into vein, each additional hour | 28 | $2,770 | $24 |
| Injection of drug or substance under skin or into muscle | 54 | $2,483 | $11 |
| Injection, iron sucrose, 1 mg | 11 | $2,023 | None |
| Red blood count, automated test | 219 | $1,627 | $4 |
| Magnesium level | 55 | $1,478 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,343 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $1,336 | $17 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 34 | $1,305 | $20 |
| Injection, fosaprepitant, 1 mg | 22 | $1,209 | None |
| Infusion into a vein for hydration, 31-60 minutes | 24 | $1,052 | $27 |
| Haptoglobin (serum protein) level | 39 | $999 | $12 |
| Hepatitis c antibody measurement | 59 | $839 | $14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 50 | $678 | $6 |
| Hepatitis b core antibody measurement | 57 | $673 | $12 |
| Injection, palonosetron hcl, 25 mcg | 26 | $630 | None |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 82 | $627 | $4 |
| Hepatitis b surface antibody measurement | 58 | $611 | $11 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 59 | $597 | $10 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $580 | $26 |
| Collection of blood sample from implanted device | 11 | $408 | $23 |
| Microscopic examination for white blood cells with manual cell count | 51 | $398 | $4 |
| Infusion into a vein for hydration, each additional hour | 21 | $358 | $10 |
| Thyroxine (thyroid chemical), free | 17 | $292 | $9 |
| Injection, granisetron hydrochloride, 100 mcg | 21 | $267 | None |
| Uric acid level, blood | 14 | $217 | $4 |
| Blood test, clotting time | 19 | $197 | $4 |
| Infusion, normal saline solution , 1000 cc | 30 | $122 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $120 | None |
| Coagulation assessment blood test, plasma or whole blood | 12 | $94 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $62 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $45 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $31 | None |
Who their Medicare patients are
776 Original Medicare patients in 2024. Average age 74 · Under 65 11% · 85 and older 11% · Women 55% · Also on Medicaid 23% · Health risk score 1.87. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 40% · Coronary heart disease 35% · Diabetes 31% · Chronic kidney disease 25% · COPD 23% · Atrial fibrillation 21% · Depression 20% · Heart failure 19% · Stroke 11% · Dementia 6%.
The office billed $10,859,979, Medicare allowed $3,439,462 and paid $2,756,237; for 190,459 services of 174 kinds; $2,313,144 of it was for drugs given in the office and $443,093 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 776 | 190,459 | 74 | 1.87 | $10,859,979 | $2,756,237 |
| 2023 | 632 | 79,983 | 74 | 1.81 | $4,426,683 | $1,086,758 |
| 2022 | 634 | 136,540 | 74 | 1.91 | $7,609,914 | $1,815,098 |
| 2021 | 584 | 129,239 | 73 | 1.99 | $6,462,701 | $1,646,164 |
| 2020 | 618 | 140,740 | 71 | 2.14 | $7,037,413 | $1,677,797 |
| 2019 | 629 | 113,381 | 72 | 2.13 | $6,622,007 | $1,790,165 |
| 2018 | 719 | 105,810 | 72 | 2.09 | $6,493,320 | $1,650,273 |
| 2017 | 762 | 152,139 | 73 | 2.03 | $7,103,804 | $1,719,842 |
| 2016 | 704 | 145,253 | 72 | 2.37 | $6,403,785 | $1,604,624 |
| 2015 | 687 | 141,934 | 72 | 2.12 | $5,669,745 | $1,403,022 |
| 2014 | 704 | 112,344 | 73 | 2.10 | $4,391,677 | $1,085,045 |
| 2013 | 739 | 99,250 | 73 | 2.04 | $4,676,172 | $1,090,124 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 54 services
| Return visit (30+ min) | 294 | $54,961 | $99 |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $15,663 | $112 |
| Short return visit (20+ min) | 163 | $14,005 | $66 |
| Blood test, comprehensive group of blood chemicals | 525 | $13,217 | $10 |
| Insertion of needle into vein for collection of blood sample | 535 | $11,743 | $8 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 519 | $9,855 | $8 |
| New patient visit (45+ min) | 59 | $7,737 | $131 |
| Ferritin (blood protein) level | 281 | $6,880 | $13 |
| Measurement of substance using immunoassay technique | 112 | $6,262 | $17 |
| Blood test, thyroid stimulating hormone (tsh) | 218 | $5,284 | $16 |
| Cyanocobalamin (vitamin b-12) level | 205 | $4,449 | $15 |
| Gammaglobulin (immune system protein) measurement | 102 | $4,402 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 38 | $3,857 | $53 |
| Folic acid level, serum | 184 | $3,775 | $14 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $3,615 | $0 |
| Iron binding capacity | 246 | $3,565 | $9 |
| New patient visit (60+ min) | 18 | $3,382 | $188 |
| Beta-2 microglobulin (protein) level | 142 | $3,378 | $16 |
| Psa (prostate specific antigen) measurement, total | 95 | $2,811 | $18 |
| Iron level | 250 | $2,701 | $6 |
| Lactate dehydrogenase (enzyme) level | 250 | $2,486 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $2,396 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,259 | $65 |
| Injection of additional new drug or substance into vein | 32 | $2,253 | $13 |
| Carcinoembryonic antigen (cea) protein level | 79 | $2,100 | $19 |
| Injection of drug or substance under skin or into muscle | 45 | $1,744 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 12 | $1,578 | $56 |
| Administration of chemotherapy into vein, each additional hour | 19 | $1,299 | $25 |
| Red blood count automated, with additional calculations | 141 | $1,179 | $5 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 22 | $918 | $20 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $918 | $66 |
| Magnesium level | 37 | $775 | $7 |
| Hepatitis c antibody measurement | 52 | $741 | $14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 42 | $691 | $6 |
| Hepatitis b core antibody measurement | 53 | $638 | $12 |
| Injection, fosaprepitant, 1 mg | 12 | $597 | None |
| Hepatitis b surface antibody measurement | 53 | $569 | $11 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 52 | $536 | $10 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 74 | $514 | $4 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $514 | $27 |
| Microscopic examination for white blood cells with manual cell count | 42 | $405 | $4 |
| Injection, palonosetron hcl, 25 mcg | 15 | $365 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $340 | $20 |
| Red blood count, automated test | 77 | $317 | $4 |
| Haptoglobin (serum protein) level | 11 | $247 | $12 |
| Coagulation function measurement, d-dimer; quantitative | 15 | $190 | $10 |
| Blood test, clotting time | 19 | $160 | $4 |
| Uric acid level, blood | 15 | $128 | $4 |
| Injection, granisetron hydrochloride, 100 mcg | 11 | $105 | None |
| Coagulation assessment blood test, plasma or whole blood | 13 | $94 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $57 | None |
| Infusion, normal saline solution , 1000 cc | 14 | $55 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 19 | $52 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 14 | $31 | None |
2022: 70 services
| Injection, denosumab, 1 mg | 22 | $72,108 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 38 | $56,100 | $850 |
| Return visit (30+ min) | 259 | $52,990 | $99 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 12 | $33,455 | None |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $30,703 | $121 |
| Short return visit (20+ min) | 213 | $21,578 | $70 |
| Blood test, comprehensive group of blood chemicals | 479 | $12,561 | $10 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 43 | $11,887 | $258 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $11,197 | $1 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 490 | $10,255 | $8 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $7,803 | $217 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $7,290 | $57 |
| Ferritin (blood protein) level | 260 | $6,519 | $13 |
| New patient visit (45+ min) | 44 | $5,789 | $132 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 40 | $5,663 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $5,606 | $60 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 11 | $5,430 | $160 |
| Blood test, thyroid stimulating hormone (tsh) | 220 | $5,323 | $17 |
| Measurement of substance using immunoassay technique | 86 | $5,143 | $17 |
| Gammaglobulin (immune system protein) measurement | 102 | $4,863 | $9 |
| New patient visit (60+ min) | 25 | $4,638 | $186 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $4,405 | $60 |
| Insertion of needle into vein for collection of blood sample | 503 | $4,238 | $3 |
| Cyanocobalamin (vitamin b-12) level | 173 | $4,079 | $15 |
| Folic acid level, serum | 158 | $3,760 | $15 |
| Injection of additional new drug or substance into vein | 48 | $3,666 | $14 |
| Iron binding capacity | 226 | $3,451 | $9 |
| Beta-2 microglobulin (protein) level | 112 | $3,241 | $16 |
| Injection of drug or substance under skin or into muscle | 66 | $3,157 | $12 |
| Psa (prostate specific antigen) measurement, total | 103 | $3,105 | $18 |
| Drawing of blood for a medical problem | 18 | $2,882 | $87 |
| Carcinoembryonic antigen (cea) protein level | 89 | $2,846 | $19 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,622 | $49 |
| Iron level | 226 | $2,555 | $6 |
| Lactate dehydrogenase (enzyme) level | 205 | $2,207 | $6 |
| Long return visit (40+ min) | 14 | $2,183 | $156 |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,174 | $25 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,152 | $113 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $2,007 | $74 |
| Injection, fosaprepitant, 1 mg | 28 | $1,535 | None |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 29 | $1,360 | $21 |
| Red blood count automated, with additional calculations | 140 | $1,275 | $5 |
| Magnesium level | 37 | $992 | $7 |
| Hepatitis c antibody measurement | 64 | $928 | $14 |
| Vitamin d-3 level | 21 | $822 | $29 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $814 | $28 |
| Hepatitis b core antibody measurement | 63 | $772 | $12 |
| Injection, palonosetron hcl, 25 mcg | 34 | $764 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 41 | $734 | $6 |
| Injection, fluorouracil, 500 mg | 13 | $729 | None |
| Hepatitis b surface antibody measurement | 63 | $688 | $11 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 63 | $662 | $10 |
| Injection, carboplatin, 50 mg | 14 | $619 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $575 | $19 |
| Injection, paclitaxel, 1 mg | 11 | $570 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $537 | $17 |
| Injection, leucovorin calcium, per 50 mg | 12 | $516 | None |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 57 | $480 | $4 |
| Microscopic examination for white blood cells with manual cell count | 41 | $431 | $4 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 14 | $412 | $21 |
| Application of on-body injector for under skin injection | 11 | $334 | $17 |
| Blood test, clotting time | 21 | $190 | $4 |
| Thyroxine (thyroid chemical), free | 13 | $178 | $9 |
| Injection, dexamethasone sodium phosphate, 1 mg | 33 | $106 | None |
| Uric acid level, blood | 11 | $98 | $4 |
| Coagulation assessment blood test, plasma or whole blood | 13 | $83 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $79 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $72 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $59 | None |
| Unclassified drugs | 13 | $23 | None |
2021: 66 services
| Injection, pembrolizumab, 1 mg | 13 | $422,711 | None |
| Return visit (30+ min) | 234 | $61,178 | $107 |
| Injection, denosumab, 1 mg | 19 | $57,448 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 11 | $40,726 | None |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 27 | $37,230 | $689 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 37 | $32,708 | $160 |
| Administration of chemotherapy into vein, 1 hour or less | 56 | $30,377 | $133 |
| Short return visit (20+ min) | 232 | $27,188 | $73 |
| Blood test, comprehensive group of blood chemicals | 453 | $14,114 | $11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 461 | $10,966 | $8 |
| New patient visit (45+ min) | 69 | $9,465 | $137 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11 | $9,154 | $1 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 35 | $9,067 | $259 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $7,528 | $221 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 38 | $6,458 | $65 |
| Ferritin (blood protein) level | 211 | $5,847 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $5,461 | $28 |
| Blood test, thyroid stimulating hormone (tsh) | 191 | $5,309 | $17 |
| Gammaglobulin (immune system protein) measurement | 86 | $4,464 | $9 |
| Insertion of needle into vein for collection of blood sample | 471 | $4,452 | $3 |
| Folic acid level, serum | 161 | $4,219 | $15 |
| Cyanocobalamin (vitamin b-12) level | 167 | $4,147 | $15 |
| Measurement of substance using immunoassay technique | 62 | $4,145 | $17 |
| Iron binding capacity | 186 | $3,059 | $9 |
| New patient visit (60+ min) | 16 | $3,017 | $189 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $3,012 | $64 |
| Carcinoembryonic antigen (cea) protein level | 77 | $2,962 | $19 |
| Injection of drug or substance under skin or into muscle | 63 | $2,938 | $12 |
| Psa (prostate specific antigen) measurement, total | 78 | $2,759 | $18 |
| Beta-2 microglobulin (protein) level | 84 | $2,573 | $16 |
| Lactate dehydrogenase (enzyme) level | 196 | $2,418 | $6 |
| Iron level | 186 | $2,265 | $6 |
| Administration of additional new drug or substance into vein using push technique | 17 | $2,106 | $55 |
| Drawing of blood for a medical problem | 13 | $2,049 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,042 | $62 |
| Injection, fosaprepitant, 1 mg | 16 | $1,876 | None |
| Injection, iron sucrose, 1 mg | 11 | $1,771 | None |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,726 | $75 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 31 | $1,706 | $21 |
| Injection of additional new drug or substance into vein | 33 | $1,590 | $15 |
| Magnesium level | 40 | $1,360 | $7 |
| Administration of chemotherapy into vein, each additional hour | 18 | $1,335 | $28 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,304 | $119 |
| Injection, palonosetron hcl, 25 mcg | 22 | $1,090 | None |
| Red blood count automated, with additional calculations | 134 | $1,086 | $6 |
| Injection, leucovorin calcium, per 50 mg | 11 | $945 | None |
| Hepatitis c antibody measurement | 65 | $942 | $14 |
| Hepatitis b core antibody measurement | 65 | $795 | $12 |
| Hepatitis b surface antibody measurement | 64 | $709 | $11 |
| Injection, zoledronic acid, 1 mg | 12 | $708 | None |
| Detection test by immunoassay technique for hepatitis b surface antigen | 65 | $692 | $10 |
| Vitamin d-3 level | 21 | $681 | $30 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 77 | $649 | $4 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 37 | $595 | $6 |
| Injection, fluorouracil, 500 mg | 12 | $576 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $487 | $19 |
| Microscopic examination for white blood cells with manual cell count | 37 | $350 | $4 |
| Infusion into a vein for hydration, each additional hour | 11 | $297 | $12 |
| Uric acid level, blood | 24 | $258 | $5 |
| Haptoglobin (serum protein) level | 13 | $252 | $13 |
| Blood test, clotting time | 22 | $129 | $4 |
| Coagulation assessment blood test, plasma or whole blood | 15 | $114 | $6 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $81 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 21 | $72 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $58 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $22 | None |
2020: 70 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 24 | $71,034 | None |
| Injection, pegfilgrastim, 6 mg | 15 | $67,748 | None |
| Injection, denosumab, 1 mg | 19 | $58,612 | None |
| Return visit (30+ min) | 230 | $45,973 | $87 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 38 | $35,398 | $159 |
| Administration of chemotherapy into vein, 1 hour or less | 72 | $33,123 | $123 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 20 | $31,079 | $676 |
| Short return visit (20+ min) | 199 | $16,384 | $54 |
| Injection, fosaprepitant, 1 mg | 30 | $13,642 | None |
| Blood test, comprehensive group of blood chemicals | 466 | $13,323 | $10 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 12 | $11,703 | $213 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 486 | $10,826 | $8 |
| New patient visit (45+ min) | 69 | $8,939 | $130 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 50 | $7,501 | $27 |
| Telephone medical discussion with physician, 11-20 minutes | 86 | $6,778 | $65 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $5,989 | $250 |
| Ferritin (blood protein) level | 228 | $5,324 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $5,112 | $116 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $4,669 | $60 |
| Cyanocobalamin (vitamin b-12) level | 188 | $4,331 | $15 |
| Insertion of needle into vein for collection of blood sample | 487 | $4,251 | $3 |
| Folic acid level, serum | 184 | $4,018 | $15 |
| Blood test, thyroid stimulating hormone (tsh) | 168 | $3,892 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 36 | $3,875 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,709 | $59 |
| Gammaglobulin (immune system protein) measurement | 85 | $3,616 | $9 |
| Measurement of substance using immunoassay technique | 58 | $3,466 | $17 |
| Injection, palonosetron hcl, 25 mcg | 35 | $3,383 | None |
| Carcinoembryonic antigen (cea) protein level | 86 | $3,362 | $19 |
| Injection of drug or substance under skin or into muscle | 81 | $3,118 | $12 |
| Iron binding capacity | 206 | $2,936 | $9 |
| Administration of chemotherapy into vein, each additional hour | 30 | $2,477 | $26 |
| Administration of additional new drug or substance into vein using push technique | 16 | $2,416 | $49 |
| Injection of additional new drug or substance into vein | 40 | $2,239 | $14 |
| Iron level | 206 | $2,173 | $6 |
| Psa (prostate specific antigen) measurement, total | 65 | $2,157 | $18 |
| Beta-2 microglobulin (protein) level | 62 | $1,705 | $16 |
| Magnesium level | 41 | $1,472 | $7 |
| Drawing of blood for a medical problem | 13 | $1,451 | $81 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 30 | $1,448 | $21 |
| Lactate dehydrogenase (enzyme) level | 136 | $1,437 | $6 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 17 | $1,037 | $61 |
| Red blood count automated, with additional calculations | 137 | $1,019 | $6 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 141 | $935 | $4 |
| Injection, iron sucrose, 1 mg | 11 | $812 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $753 | $18 |
| Injection, fluorouracil, 500 mg | 12 | $739 | None |
| Vitamin d-3 level | 21 | $708 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $694 | $19 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $634 | $33 |
| Hepatitis c antibody measurement | 44 | $600 | $14 |
| Injection, zoledronic acid, 1 mg | 12 | $553 | None |
| Hepatitis b core antibody measurement | 45 | $519 | $12 |
| Hepatitis b surface antibody measurement | 45 | $462 | $10 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 45 | $445 | $10 |
| Irrigation of implanted venous access drug delivery device | 13 | $420 | $22 |
| Haptoglobin (serum protein) level | 17 | $374 | $12 |
| Administration of influenza virus vaccine | 18 | $323 | $18 |
| Infusion into a vein for hydration, each additional hour | 16 | $322 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 18 | $276 | $6 |
| Uric acid level, blood | 22 | $215 | $4 |
| Thyroxine (thyroid chemical), free | 18 | $206 | $9 |
| Blood test, clotting time | 32 | $179 | $4 |
| Coagulation assessment blood test, plasma or whole blood | 26 | $167 | $6 |
| Microscopic examination for white blood cells with manual cell count | 18 | $158 | $4 |
| Injection, dexamethasone sodium phosphate, 1 mg | 37 | $107 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 11 | $100 | $8 |
| Infusion, normal saline solution , 1000 cc | 20 | $84 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $73 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $23 | None |
2019: 71 services
| Injection, pembrolizumab, 1 mg | 11 | $348,087 | None |
| Injection, nivolumab, 1 mg | 12 | $300,907 | None |
| Injection, pegfilgrastim, 6 mg | 16 | $90,298 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20 | $66,593 | None |
| Return visit (30+ min) | 262 | $50,609 | $86 |
| Injection, denosumab, 1 mg | 12 | $46,907 | None |
| Administration of chemotherapy into vein, 1 hour or less | 66 | $30,427 | $120 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 24 | $30,017 | $625 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 33 | $28,381 | $157 |
| Short return visit (20+ min) | 246 | $22,477 | $57 |
| Blood test, comprehensive group of blood chemicals | 478 | $14,432 | $11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 508 | $12,173 | $8 |
| New patient visit (45+ min) | 78 | $10,158 | $130 |
| Injection, aprepitant, 1 mg | 22 | $9,129 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 31 | $7,731 | $242 |
| Ferritin (blood protein) level | 222 | $5,999 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 41 | $5,591 | $27 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 44 | $5,350 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 30 | $4,974 | $61 |
| Cyanocobalamin (vitamin b-12) level | 177 | $4,808 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,683 | $62 |
| Injection, palonosetron hcl, 25 mcg | 29 | $4,539 | None |
| Folic acid level, serum | 169 | $4,387 | $16 |
| Insertion of needle into vein for collection of blood sample | 505 | $4,320 | $3 |
| Iron binding capacity | 210 | $3,513 | $10 |
| Carcinoembryonic antigen (cea) protein level | 93 | $3,308 | $21 |
| Injection of drug or substance under skin or into muscle | 76 | $3,283 | $14 |
| Blood test, thyroid stimulating hormone (tsh) | 127 | $3,166 | $18 |
| Iron level | 210 | $2,601 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $2,482 | $58 |
| Psa (prostate specific antigen) measurement, total | 85 | $2,424 | $20 |
| Lactate dehydrogenase (enzyme) level | 244 | $2,239 | $7 |
| Gammaglobulin (immune system protein) measurement | 48 | $2,047 | $10 |
| Measurement of substance using immunoassay technique | 34 | $1,794 | $17 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 38 | $1,777 | $22 |
| Beta-2 microglobulin (protein) level | 66 | $1,761 | $18 |
| Long return visit (40+ min) | 14 | $1,737 | $124 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,217 | $51 |
| Red blood count automated, with additional calculations | 134 | $1,165 | $6 |
| Injection of additional new drug or substance into vein | 36 | $1,123 | $14 |
| Magnesium level | 37 | $1,115 | $7 |
| Administration of chemotherapy into vein, each additional hour | 19 | $1,080 | $26 |
| Injection, iron sucrose, 1 mg | 12 | $1,078 | None |
| Ct scan of chest with contrast | 11 | $918 | $83 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $836 | $19 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 126 | $723 | $4 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $665 | $27 |
| Influenza vaccine, inactivated | 11 | $642 | $58 |
| Vitamin d-3 level | 16 | $612 | $32 |
| Irrigation of implanted venous access drug delivery device | 19 | $571 | $22 |
| Hepatitis c antibody measurement | 36 | $559 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $527 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $525 | $33 |
| Injection, carboplatin, 50 mg | 13 | $518 | None |
| Hepatitis b core antibody measurement | 35 | $459 | $13 |
| Hepatitis b surface antibody measurement | 35 | $409 | $12 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 35 | $394 | $11 |
| Rheumatoid factor level | 53 | $383 | $6 |
| Haptoglobin (serum protein) level | 21 | $370 | $14 |
| Blood test, clotting time | 45 | $355 | $4 |
| Coagulation assessment blood test, plasma or whole blood | 30 | $288 | $7 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 18 | $225 | $7 |
| Administration of influenza virus vaccine | 12 | $210 | $18 |
| Blood test, basic group of blood chemicals (calcium, total) | 13 | $157 | $9 |
| Uric acid level, blood | 15 | $153 | $5 |
| Microscopic examination for white blood cells with manual cell count | 18 | $120 | $4 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 12 | $114 | $0 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $88 | None |
| Infusion, normal saline solution , 1000 cc | 19 | $60 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $59 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $30 | None |
2018: 73 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 26 | $81,651 | None |
| Return visit (30+ min) | 359 | $67,318 | $83 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 43 | $56,101 | $623 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 46 | $42,650 | $157 |
| Injection, denosumab, 1 mg | 14 | $40,034 | None |
| Administration of chemotherapy into vein, 1 hour or less | 56 | $27,606 | $121 |
| Short return visit (20+ min) | 259 | $19,817 | $54 |
| Blood test, comprehensive group of blood chemicals | 561 | $18,317 | $13 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 597 | $15,955 | $9 |
| Injection, palonosetron hcl, 25 mcg | 27 | $12,795 | None |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 45 | $11,401 | $243 |
| New patient visit (45+ min) | 76 | $10,108 | $133 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $9,690 | $206 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $8,023 | $60 |
| Ferritin (blood protein) level | 263 | $7,998 | $16 |
| Lactate dehydrogenase (enzyme) level | 441 | $7,952 | $7 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 61 | $7,397 | $112 |
| Unclassified drugs | 16 | $6,290 | None |
| Carcinoembryonic antigen (cea) protein level | 129 | $6,217 | $23 |
| Cyanocobalamin (vitamin b-12) level | 192 | $5,855 | $18 |
| Folic acid level, serum | 177 | $5,284 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 34 | $5,269 | $57 |
| Insertion of needle into vein for collection of blood sample | 592 | $5,033 | $3 |
| Iron binding capacity | 248 | $4,735 | $11 |
| Injection of drug or substance under skin or into muscle | 78 | $4,280 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $3,709 | $27 |
| Injection of additional new drug or substance into vein | 39 | $3,705 | $15 |
| Beta-2 microglobulin (protein) level | 115 | $3,523 | $20 |
| Iron level | 248 | $3,508 | $8 |
| Blood test, thyroid stimulating hormone (tsh) | 124 | $3,273 | $20 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $3,254 | $58 |
| Administration of additional new drug or substance into vein using push technique | 21 | $2,902 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,784 | $87 |
| Administration of chemotherapy into vein, each additional hour | 25 | $2,536 | $26 |
| Gammaglobulin (immune system protein) measurement | 60 | $2,475 | $11 |
| Vitamin d-3 level | 51 | $2,400 | $36 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 44 | $2,368 | $25 |
| Psa (prostate specific antigen) measurement, total | 64 | $2,248 | $22 |
| Drawing of blood for a medical problem | 18 | $2,192 | $84 |
| Red blood count automated, with additional calculations | 176 | $2,089 | $7 |
| Long return visit (40+ min) | 18 | $1,997 | $111 |
| Injection, leucovorin calcium, per 50 mg | 12 | $1,752 | None |
| Ct scan of chest with contrast | 13 | $1,263 | $84 |
| Injection, iron sucrose, 1 mg | 15 | $1,215 | None |
| Infusion into a vein for hydration, 31-60 minutes | 13 | $1,192 | $40 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $1,056 | $19 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $1,002 | $18 |
| Irrigation of implanted venous access drug delivery device | 21 | $909 | $22 |
| Influenza vaccine split virus, preservative free | 15 | $772 | $51 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 115 | $760 | $4 |
| Hepatitis c antibody measurement | 43 | $742 | $17 |
| Magnesium level | 40 | $729 | $8 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $675 | $23 |
| Injection, fluorouracil, 500 mg | 13 | $632 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 13 | $617 | $17 |
| Hepatitis b surface antibody measurement | 43 | $559 | $13 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 43 | $537 | $12 |
| Haptoglobin (serum protein) level | 19 | $517 | $15 |
| Hepatitis b core antibody measurement | 32 | $467 | $15 |
| Blood test, clotting time | 41 | $432 | $5 |
| Infusion into a vein for hydration, each additional hour | 14 | $375 | $12 |
| Administration of influenza virus vaccine | 17 | $368 | $22 |
| Blood test, basic group of blood chemicals (calcium, total) | 17 | $338 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 28 | $305 | $8 |
| Rheumatoid factor level | 39 | $288 | $7 |
| Coagulation assessment blood test, plasma or whole blood | 23 | $182 | $7 |
| Microscopic examination for white blood cells with manual cell count | 28 | $162 | $4 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 14 | $143 | $0 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 26 | $112 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 25 | $78 | None |
| Uric acid level, blood | 11 | $77 | $5 |
| Infusion, normal saline solution , 1000 cc | 13 | $53 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 26 | $36 | None |
2017: 73 services
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 26 | $106,496 | None |
| Return visit (30+ min) | 371 | $69,440 | $83 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 65 | $51,430 | $157 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 37 | $47,225 | $605 |
| Administration of chemotherapy into vein, 1 hour or less | 67 | $32,873 | $116 |
| Injection, denosumab, 1 mg | 14 | $28,709 | None |
| Short return visit (20+ min) | 256 | $23,427 | $55 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 630 | $20,609 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 53 | $15,599 | $58 |
| Injection, palonosetron hcl, 25 mcg | 33 | $14,552 | None |
| Blood test, comprehensive group of blood chemicals | 583 | $14,280 | $9 |
| New patient visit (60+ min) | 77 | $12,716 | $165 |
| Ferritin (blood protein) level | 324 | $11,363 | $18 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 12 | $11,302 | $1 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 39 | $10,137 | $241 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $9,912 | $87 |
| Cyanocobalamin (vitamin b-12) level | 270 | $9,878 | $20 |
| Folic acid level, serum | 253 | $8,830 | $19 |
| Injection of drug or substance under skin or into muscle | 91 | $8,451 | $21 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 45 | $7,894 | $26 |
| Gammaglobulin (immune system protein) measurement | 122 | $7,627 | $13 |
| Iron binding capacity | 319 | $7,156 | $12 |
| Carcinoembryonic antigen (cea) protein level | 139 | $6,174 | $25 |
| Insertion of needle into vein for collection of blood sample | 632 | $5,795 | $3 |
| Blood test, thyroid stimulating hormone (tsh) | 159 | $5,489 | $23 |
| Lactate dehydrogenase (enzyme) level | 536 | $5,385 | $4 |
| Iron level | 319 | $5,298 | $9 |
| Beta-2 microglobulin (protein) level | 129 | $5,242 | $22 |
| Long return visit (40+ min) | 34 | $4,112 | $117 |
| Administration of chemotherapy into vein, each additional hour | 34 | $3,835 | $24 |
| Red blood count automated, with additional calculations | 259 | $3,648 | $7 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,632 | $113 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,551 | $169 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $3,423 | $54 |
| Psa (prostate specific antigen) measurement, total | 73 | $3,042 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 24 | $3,034 | $16 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 56 | $2,641 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,634 | $60 |
| Injection of additional new drug or substance into vein | 37 | $2,628 | $19 |
| Magnesium level | 88 | $2,577 | $9 |
| Vitamin d-3 level | 54 | $2,562 | $39 |
| New patient visit (45+ min) | 17 | $2,110 | $124 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,906 | $49 |
| Injection, iron sucrose, 1 mg | 19 | $1,847 | None |
| Drawing of blood for a medical problem | 12 | $1,594 | $72 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,594 | $50 |
| Injection, zoledronic acid, 1 mg | 16 | $1,389 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,271 | $28 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 141 | $1,224 | $5 |
| Influenza vaccine split virus, preservative free | 22 | $1,045 | $45 |
| Injection, paclitaxel, 1 mg | 12 | $1,016 | None |
| Blood test, basic group of blood chemicals (calcium, total) | 44 | $928 | $8 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $882 | $17 |
| Injection, carboplatin, 50 mg | 14 | $745 | None |
| Administration of influenza virus vaccine | 23 | $646 | $27 |
| Irrigation of implanted venous access drug delivery device | 25 | $613 | $19 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 12 | $588 | $28 |
| Hepatitis b surface antibody measurement | 39 | $578 | $14 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 39 | $556 | $14 |
| Infusion into a vein for hydration, each additional hour | 15 | $554 | $13 |
| Alpha-fetoprotein (afp) level, serum | 16 | $470 | $21 |
| Blood test, clotting time | 17 | $433 | $5 |
| Injection, magnesium sulfate, per 500 mg | 21 | $351 | None |
| Haptoglobin (serum protein) level | 12 | $321 | $17 |
| Unclassified drugs | 16 | $287 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 33 | $245 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 18 | $164 | $7 |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $122 | None |
| Microscopic examination for white blood cells with manual cell count | 18 | $97 | $4 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 12 | $81 | None |
| Infusion, normal saline solution , 1000 cc | 16 | $77 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $41 | None |
| Infusion, normal saline solution, 250 cc | 14 | $10 | None |
2016: 78 services
| Injection, rituximab, 100 mg | 12 | $132,844 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 30 | $130,633 | None |
| Injection, pegfilgrastim, 6 mg | 13 | $83,512 | None |
| Return visit (30+ min) | 310 | $69,105 | $85 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 31 | $38,850 | $589 |
| Administration of chemotherapy into vein, 1 hour or less | 74 | $34,296 | $114 |
| Short return visit (20+ min) | 226 | $24,453 | $56 |
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 41 | $23,677 | $157 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 571 | $19,894 | $10 |
| New patient visit (60+ min) | 87 | $14,453 | $166 |
| Injection, palonosetron hcl, 25 mcg | 33 | $14,204 | None |
| Blood test, comprehensive group of blood chemicals | 516 | $13,572 | $9 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 61 | $12,286 | $59 |
| Ferritin (blood protein) level | 274 | $10,647 | $18 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 41 | $10,137 | $230 |
| Cyanocobalamin (vitamin b-12) level | 236 | $9,778 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 61 | $9,010 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $8,930 | $86 |
| Injection of drug or substance under skin or into muscle | 86 | $8,468 | $21 |
| Folic acid level, serum | 218 | $8,446 | $18 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 11 | $7,723 | $1 |
| Iron binding capacity | 267 | $6,699 | $12 |
| Blood test, thyroid stimulating hormone (tsh) | 144 | $5,652 | $22 |
| Insertion of needle into vein for collection of blood sample | 569 | $5,639 | $3 |
| Lactate dehydrogenase (enzyme) level | 476 | $5,473 | $4 |
| Carcinoembryonic antigen (cea) protein level | 111 | $5,246 | $25 |
| Iron level | 267 | $4,959 | $9 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $4,517 | $53 |
| Beta-2 microglobulin (protein) level | 112 | $4,428 | $22 |
| Gammaglobulin (immune system protein) measurement | 73 | $4,408 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,007 | $167 |
| Administration of prolonged chemotherapy into vein | 12 | $3,718 | $120 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $3,683 | $61 |
| Red blood count automated, with additional calculations | 212 | $3,482 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $3,265 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,721 | $113 |
| Long return visit (40+ min) | 21 | $2,384 | $114 |
| Drawing of blood for a medical problem | 16 | $2,303 | $79 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $2,283 | $49 |
| Biopsy of bone marrow | 15 | $2,273 | $142 |
| Psa (prostate specific antigen) measurement, total | 58 | $2,229 | $24 |
| Administration of chemotherapy into vein, each additional hour | 33 | $2,137 | $24 |
| Injection of additional new drug or substance into vein | 42 | $2,100 | $19 |
| Administration of additional new drug or substance into vein using push technique | 17 | $1,956 | $53 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $1,955 | $16 |
| Influenza vaccine split virus, preservative free | 47 | $1,872 | $40 |
| Magnesium level | 73 | $1,851 | $9 |
| Injection, iron sucrose, 1 mg | 22 | $1,667 | None |
| Vitamin d-3 level | 36 | $1,557 | $39 |
| Injection, zoledronic acid, 1 mg | 16 | $1,497 | None |
| Administration of influenza virus vaccine | 54 | $1,438 | $27 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 31 | $1,422 | $27 |
| Injection, paclitaxel, 1 mg | 17 | $1,078 | None |
| Irrigation of implanted venous access drug delivery device | 28 | $985 | $19 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 121 | $970 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 33 | $884 | $17 |
| Blood test, basic group of blood chemicals (calcium, total) | 33 | $636 | $8 |
| Infusion into a vein for hydration, each additional hour | 14 | $633 | $13 |
| Hepatitis b surface antibody measurement | 40 | $631 | $14 |
| Detection test by immunoassay technique for hepatitis b surface antigen | 40 | $607 | $14 |
| Injection, carboplatin, 50 mg | 11 | $476 | None |
| Blood test, clotting time | 29 | $446 | $5 |
| Injection, fluorouracil, 500 mg | 12 | $427 | None |
| Alpha-fetoprotein (afp) level, serum | 11 | $421 | $22 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 33 | $401 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $329 | $17 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 11 | $186 | $17 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 15 | $166 | $10 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 13 | $138 | $0 |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $136 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 13 | $102 | $8 |
| Injection, magnesium sulfate, per 500 mg | 19 | $78 | None |
| Microscopic examination for white blood cells with manual cell count | 13 | $60 | $5 |
| 5% dextrose/normal saline (500 ml = 1 unit) | 11 | $49 | None |
| Unclassified drugs | 19 | $43 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $41 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $29 | None |
| Infusion, normal saline solution, 250 cc | 11 | $9 | None |
2015: 67 services
| Injection, pegfilgrastim, 6 mg | 25 | $161,631 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 40 | $126,061 | None |
| Return visit (30+ min) | 282 | $68,339 | $85 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $31,498 | $115 |
| Short return visit (20+ min) | 267 | $30,497 | $54 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 547 | $22,284 | $10 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 20 | $17,844 | None |
| Blood test, comprehensive group of blood chemicals | 493 | $14,946 | $9 |
| New patient visit (60+ min) | 79 | $12,863 | $163 |
| Injection of drug or substance under skin or into muscle | 105 | $11,776 | $21 |
| Injection, palonosetron hcl, 25 mcg | 28 | $11,589 | None |
| Ferritin (blood protein) level | 244 | $9,557 | $18 |
| Cyanocobalamin (vitamin b-12) level | 216 | $9,011 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 46 | $9,001 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $8,173 | $86 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 47 | $8,157 | $25 |
| Folic acid level, serum | 194 | $7,502 | $18 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $7,482 | $59 |
| Insertion of needle into vein for collection of blood sample | 551 | $6,436 | $3 |
| Lactate dehydrogenase (enzyme) level | 461 | $6,037 | $4 |
| Iron binding capacity | 239 | $6,005 | $12 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,405 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $4,823 | $59 |
| Carcinoembryonic antigen (cea) protein level | 109 | $4,562 | $25 |
| Injection, zoledronic acid, 1 mg | 17 | $4,493 | None |
| Iron level | 240 | $4,458 | $9 |
| Beta-2 microglobulin (protein) level | 107 | $4,294 | $22 |
| Blood test, thyroid stimulating hormone (tsh) | 103 | $3,904 | $22 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $3,714 | $52 |
| Gammaglobulin (immune system protein) measurement | 58 | $3,174 | $12 |
| Red blood count automated, with additional calculations | 198 | $3,013 | $7 |
| Biopsy of bone marrow | 17 | $2,447 | $136 |
| Magnesium level | 71 | $2,161 | $9 |
| Long return visit (40+ min) | 17 | $2,064 | $121 |
| Injection of additional new drug or substance into vein | 36 | $1,932 | $19 |
| Psa (prostate specific antigen) measurement, total | 45 | $1,871 | $24 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,701 | $113 |
| Infusion into a vein for hydration, 31-60 minutes | 21 | $1,614 | $49 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 29 | $1,365 | $27 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,231 | $16 |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,209 | $53 |
| Administration of chemotherapy into vein, each additional hour | 21 | $1,157 | $24 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,109 | $85 |
| Injection, iron sucrose, 1 mg | 12 | $1,090 | None |
| Irrigation of implanted venous access drug delivery device | 28 | $965 | $20 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $936 | $32 |
| Administration of influenza virus vaccine | 32 | $855 | $27 |
| Blood test, basic group of blood chemicals (calcium, total) | 43 | $845 | $9 |
| Injection, paclitaxel, 1 mg | 12 | $800 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 27 | $784 | $17 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 102 | $746 | $5 |
| Blood test, clotting time | 30 | $728 | $5 |
| Infusion into a vein for hydration, each additional hour | 24 | $646 | $13 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 12 | $611 | $28 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 24 | $372 | $15 |
| Prostate cancer screening; prostate specific antigen test (psa) | 14 | $343 | $25 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 32 | $323 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 17 | $187 | $10 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 20 | $171 | $8 |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $155 | None |
| Microscopic examination for white blood cells with manual cell count | 20 | $101 | $5 |
| Injection, magnesium sulfate, per 500 mg | 16 | $69 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 23 | $39 | None |
| Infusion, normal saline solution , 1000 cc | 15 | $38 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 17 | $38 | None |
| Unclassified drugs | 13 | $30 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 11 | $29 | None |
2014: 67 services
| Injection, rituximab, 100 mg | 12 | $103,106 | None |
| Injection, pegfilgrastim, 6 mg | 17 | $86,481 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 39 | $63,999 | None |
| Return visit (30+ min) | 270 | $58,224 | $83 |
| Short return visit (20+ min) | 264 | $31,240 | $55 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 19 | $28,925 | None |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $23,105 | $110 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 534 | $18,960 | $10 |
| Injection, palonosetron hcl, 25 mcg | 32 | $13,619 | None |
| New patient visit (60+ min) | 86 | $13,556 | $158 |
| Blood test, comprehensive group of blood chemicals | 478 | $12,155 | $9 |
| Radiation treatment delivery, three or more treatment areas | 17 | $9,274 | $211 |
| Injection of drug or substance under skin or into muscle | 94 | $9,181 | $20 |
| Ferritin (blood protein) level | 233 | $8,932 | $18 |
| Injection, zoledronic acid, 1 mg | 20 | $8,837 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 76 | $8,219 | $58 |
| Cyanocobalamin (vitamin b-12) level | 196 | $8,124 | $20 |
| Folic acid level, serum | 189 | $7,262 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 54 | $6,647 | $24 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $6,208 | $83 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $5,972 | $57 |
| Iron binding capacity | 231 | $5,695 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 37 | $5,639 | $55 |
| Insertion of needle into vein for collection of blood sample | 536 | $5,529 | $3 |
| Lactate dehydrogenase (enzyme) level | 449 | $5,176 | $4 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $4,720 | $157 |
| Carcinoembryonic antigen (cea) protein level | 110 | $4,621 | $25 |
| Iron level | 231 | $4,206 | $9 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $4,146 | $52 |
| Blood test, thyroid stimulating hormone (tsh) | 125 | $4,076 | $22 |
| Beta-2 microglobulin (protein) level | 115 | $3,725 | $22 |
| Long return visit (40+ min) | 19 | $2,371 | $113 |
| Injection of additional new drug or substance into vein | 43 | $2,312 | $18 |
| Drawing of blood for a medical problem | 12 | $2,164 | $80 |
| Biopsy of bone marrow | 18 | $2,117 | $118 |
| Psa (prostate specific antigen) measurement, total | 49 | $1,776 | $24 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 14 | $1,754 | None |
| Administration of chemotherapy into vein, each additional hour | 24 | $1,669 | $23 |
| Magnesium level | 69 | $1,604 | $9 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,585 | $113 |
| Continuing radiation therapy consultation per week | 13 | $1,195 | $63 |
| Ct scan of chest with contrast | 11 | $1,123 | $94 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 24 | $1,113 | $28 |
| Irrigation of implanted venous access drug delivery device | 30 | $891 | $18 |
| Blood test, basic group of blood chemicals (calcium, total) | 55 | $887 | $8 |
| Administration of additional new drug or substance into vein using push technique | 11 | $820 | $51 |
| Injection, paclitaxel, 30 mg | 11 | $766 | None |
| Injection, carboplatin, 50 mg | 12 | $752 | None |
| Administration of influenza virus vaccine | 23 | $598 | $26 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 91 | $593 | $5 |
| Blood test, clotting time | 33 | $589 | $5 |
| Red blood count automated, with additional calculations | 60 | $583 | $7 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $546 | $32 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 39 | $507 | $8 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $481 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 12 | $389 | $16 |
| Infusion into a vein for hydration, each additional hour | 13 | $351 | $13 |
| Microscopic examination for white blood cells with manual cell count | 39 | $299 | $5 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11 | $228 | $0 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 15 | $226 | $15 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 30 | $177 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 17 | $170 | $10 |
| Injection, dexamethasone sodium phosphate, 1 mg | 36 | $141 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $37 | None |
| Unclassified drugs | 13 | $28 | None |
| Injection, magnesium sulfate, per 500 mg | 15 | $20 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 12 | $15 | None |
2013: 64 services
| Injection, pegfilgrastim, 6 mg | 17 | $73,702 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 37 | $61,139 | None |
| Return visit (30+ min) | 281 | $51,031 | $81 |
| Short return visit (20+ min) | 341 | $37,812 | $54 |
| Administration of chemotherapy into vein, 1 hour or less | 69 | $32,315 | $114 |
| Compensator-based beam modulation radiation treatment delivery per session | 11 | $27,902 | $340 |
| Radiation treatment delivery, three or more treatment areas | 22 | $26,025 | $219 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 583 | $21,862 | $10 |
| Injection, palonosetron hcl, 25 mcg | 40 | $19,660 | None |
| New patient visit (60+ min) | 94 | $14,758 | $157 |
| Zoldedronic acid 1mg | 14 | $13,612 | $131 |
| Blood test, comprehensive group of blood chemicals | 518 | $12,616 | $9 |
| Fecal microbiota, live - jslm, 1 ml | 13 | $10,817 | None |
| Injection of drug or substance under skin or into muscle | 92 | $9,787 | $21 |
| Ferritin (blood protein) level | 220 | $8,190 | $18 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $8,007 | $58 |
| Cyanocobalamin (vitamin b-12) level | 197 | $7,639 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 68 | $7,112 | $56 |
| Folic acid level, serum | 180 | $6,781 | $18 |
| Insertion of needle into vein for collection of blood sample | 589 | $6,491 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 43 | $5,742 | $58 |
| Lactate dehydrogenase (enzyme) level | 495 | $5,398 | $4 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $5,339 | $56 |
| Iron binding capacity | 219 | $5,068 | $12 |
| Carcinoembryonic antigen (cea) protein level | 129 | $5,013 | $26 |
| Blood test, thyroid stimulating hormone (tsh) | 129 | $4,028 | $23 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,026 | $155 |
| Iron level | 219 | $3,752 | $9 |
| Beta-2 microglobulin (protein) level | 107 | $3,482 | $22 |
| Injection of additional new drug or substance into vein | 46 | $3,164 | $18 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $2,890 | $25 |
| Biopsy of bone marrow | 21 | $2,797 | $133 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,389 | $109 |
| Administration of chemotherapy into vein, each additional hour | 30 | $2,373 | $24 |
| Infusion into a vein for hydration, 31-60 minutes | 17 | $2,203 | $49 |
| Administration of additional new drug or substance into vein using push technique | 11 | $2,194 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,127 | $82 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 49 | $1,915 | $28 |
| Long return visit (40+ min) | 16 | $1,780 | $111 |
| Injection, paclitaxel, 30 mg | 21 | $1,756 | None |
| Continuing radiation therapy consultation per week | 26 | $1,628 | $37 |
| Psa (prostate specific antigen) measurement, total | 47 | $1,620 | $25 |
| Magnesium level | 47 | $1,277 | $9 |
| Blood test, basic group of blood chemicals (calcium, total) | 48 | $1,103 | $9 |
| Irrigation of implanted venous access drug delivery device | 30 | $945 | $20 |
| Administration of influenza virus vaccine | 32 | $854 | $27 |
| Blood test, clotting time | 37 | $797 | $5 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $766 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 48 | $765 | $8 |
| Injection, carboplatin, 50 mg | 17 | $720 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $649 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $587 | $15 |
| Infusion into a vein for hydration, each additional hour | 17 | $523 | $13 |
| Microscopic examination for white blood cells with manual cell count | 48 | $453 | $5 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 12 | $422 | $28 |
| Red blood cell sedimentation rate, to detect inflammation, non-automated | 60 | $370 | $5 |
| X-ray during radiation therapy | 20 | $361 | $12 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 28 | $330 | $12 |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 21 | $211 | $10 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 29 | $129 | None |
| 5% dextrose/normal saline (500 ml = 1 unit) | 15 | $42 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $33 | None |
| Injection, magnesium sulfate, per 500 mg | 18 | $27 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $20 | None |
Medicaid work
$20,463 in 2024
Medicaid paid $20,463 for 1,794 billed services this clinician did in 2024, up to 42 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 266 | $9,683 |
| COMPREHENSIVE METABOLIC PANEL | 317 | $3,017 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 464 | $2,732 |
| Short return visit (20+ min) | 55 | $2,624 |
| Lactate dehydrogenase (LD), (LDH) | 114 | $602 |
| Measurement of ferritin | 34 | $450 |
| Measurement of iron | 49 | $296 |
| IRON BINDING CAPACITY | 35 | $284 |
| Measurement of folic acid in serum | 15 | $218 |
| VITAMIN B-12 | 13 | $179 |
| Thyroid stimulating hormone (TSH) | 13 | $173 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 401 | $107 |
| 2024 | 1,794 | 13 | 42 | $20,463 |
| 2023 | 934 | 7 | 35 | $10,754 |
| 2022 | 1,068 | 7 | 32 | $13,209 |
| 2021 | 1,113 | 11 | 31 | $15,961 |
| 2020 | 1,081 | 6 | 36 | $16,421 |
| 2019 | 981 | 6 | 32 | $13,820 |
| 2018 | 766 | 6 | 25 | $7,468 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 56 | $4,222 |
| Return visit (30+ min) | 105 | $2,907 |
| COMPREHENSIVE METABOLIC PANEL | 220 | $1,846 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 247 | $1,502 |
| Measurement of ferritin | 12 | $153 |
| Lactate dehydrogenase (LD), (LDH) | 17 | $79 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 277 | $45 |
2022
| Short return visit (20+ min) | 114 | $5,757 |
| COMPREHENSIVE METABOLIC PANEL | 314 | $2,763 |
| Return visit (30+ min) | 58 | $2,337 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 327 | $1,976 |
| Lactate dehydrogenase (LD), (LDH) | 39 | $192 |
| Measurement of ferritin | 12 | $142 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 204 | $43 |
2021
| Short return visit (20+ min) | 152 | $7,167 |
| Return visit (30+ min) | 134 | $3,332 |
| COMPREHENSIVE METABOLIC PANEL | 266 | $2,493 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 259 | $1,788 |
| Measurement of ferritin | 26 | $341 |
| Lactate dehydrogenase (LD), (LDH) | 39 | $208 |
| VITAMIN B-12 | 12 | $181 |
| Measurement of folic acid in serum | 12 | $176 |
| IRON BINDING CAPACITY | 14 | $123 |
| Measurement of iron | 14 | $91 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 185 | $60 |
2020
| Short return visit (20+ min) | 146 | $5,723 |
| Return visit (30+ min) | 115 | $5,527 |
| COMPREHENSIVE METABOLIC PANEL | 261 | $2,524 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 346 | $2,424 |
| Measurement of ferritin | 12 | $164 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 201 | $60 |
2019
| Return visit (30+ min) | 155 | $6,023 |
| Short return visit (20+ min) | 137 | $2,893 |
| COMPREHENSIVE METABOLIC PANEL | 249 | $2,671 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 300 | $2,107 |
| Lactate dehydrogenase (LD), (LDH) | 12 | $69 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 128 | $57 |
2018
| COMPREHENSIVE METABOLIC PANEL | 193 | $2,279 |
| Short return visit (20+ min) | 70 | $1,780 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 213 | $1,515 |
| Lactate dehydrogenase (LD), (LDH) | 159 | $1,017 |
| Return visit (30+ min) | 64 | $862 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 67 | $15 |
Drugs they prescribed that Part D paid
$3,021,300
Pharmacies billed $3,021,300 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
579 generic and 232 brand-name prescriptions · $3,021,300 in drug cost · 24 antibiotic prescriptions to 13 people · 14 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 43 | $590,098 | $13,723 |
| Lenalidomide | 41 | $472,476 | $11,524 |
| Xtandi | 24 | $330,112 | $13,755 |
| Erleada | 21 | $290,204 | $13,819 |
| Imbruvica | 14 | $228,993 | $16,357 |
See all 24 drugs
| Brukinsa | 43 | $590,098 | $13,723 |
| Lenalidomide | 41 | $472,476 | $11,524 |
| Xtandi | 24 | $330,112 | $13,755 |
| Erleada | 21 | $290,204 | $13,819 |
| Imbruvica | 14 | $228,993 | $16,357 |
| Jakafi | 13 | $206,964 | $15,920 |
| Abiraterone Acetate | 46 | $202,939 | $4,412 |
| Venclexta | 11 | $163,745 | $14,886 |
| Eliquis | 48 | $27,974 | $583 |
| Enoxaparin | 14 | $3,861 | $276 |
| Hydroxyurea | 60 | $870 | $15 |
| Dexamethasone | 55 | $691 | $13 |
| Potassium Chloride | 43 | $546 | $13 |
| Megestrol Acetate | 11 | $450 | $41 |
| Prochlorperazine Maleate | 23 | $353 | $15 |
| Ondansetron Odt | 26 | $257 | $10 |
| Olanzapine | 14 | $242 | $17 |
| Anastrozole | 27 | $225 | $8 |
| Tamoxifen Citrate | 12 | $211 | $18 |
| Methylprednisolone | 23 | $168 | $7 |
| Allopurinol | 27 | $129 | $5 |
| Prednisone | 47 | $121 | $3 |
| Levofloxacin | 15 | $46 | $3 |
| Magnesium Sulfate | 17 | $31 | $2 |
Year by year
| 2024 | 811 | 128 | None | 29% | $3,021,300 |
| 2023 | 635 | 105 | None | 32% | $2,395,952 |
| 2022 | 599 | 102 | 7% (39) | 30% | $1,733,583 |
| 2021 | 579 | 113 | 4% (20) | 32% | $2,074,331 |
| 2020 | 607 | 98 | 4% (22) | 27% | $1,636,779 |
| 2019 | 650 | 97 | None | 27% | $1,541,396 |
| 2018 | 692 | 108 | None | 25% | $1,168,324 |
| 2017 | 463 | 98 | 3% (13) | 14% | $455,076 |
| 2016 | 365 | 86 | 4% (13) | 9% | $125,200 |
| 2015 | 324 | 87 | None | 21% | $480,419 |
| 2014 | 435 | 97 | 7% (32) | None | $403,699 |
| 2013 | 409 | 96 | 4% (16) | None | $152,972 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Lenalidomide | 32 | $414,688 | $12,959 |
| Imbruvica | 21 | $364,693 | $17,366 |
| Brukinsa | 23 | $287,766 | $12,512 |
| Jakafi | 14 | $265,680 | $18,977 |
| Revlimid | 17 | $254,269 | $14,957 |
| Xtandi | 15 | $196,628 | $13,109 |
| Abiraterone Acetate | 35 | $179,187 | $5,120 |
| Eliquis | 28 | $11,613 | $415 |
| Xarelto | 11 | $6,447 | $586 |
| Hydroxyurea | 66 | $1,211 | $18 |
| Anastrozole | 24 | $742 | $31 |
| Dexamethasone | 39 | $692 | $18 |
| Potassium Chloride | 32 | $649 | $20 |
| Prednisone | 52 | $245 | $5 |
| Ondansetron Odt | 12 | $229 | $19 |
| Prochlorperazine Maleate | 11 | $149 | $14 |
| Magnesium Sulfate | 49 | $97 | $2 |
| Folic Acid | 11 | $26 | $2 |
2022: 15 drugs
| Revlimid | 50 | $689,977 | $13,800 |
| Imbruvica | 40 | $615,012 | $15,375 |
| Abiraterone Acetate | 31 | $156,313 | $5,042 |
| Eliquis | 36 | $16,538 | $459 |
| Hydroxyurea | 77 | $1,092 | $14 |
| Anastrozole | 27 | $869 | $32 |
| Ondansetron Odt | 20 | $634 | $32 |
| Dexamethasone | 28 | $608 | $22 |
| Potassium Chloride | 21 | $355 | $17 |
| Prednisone | 45 | $336 | $7 |
| Oxycodone | 17 | $321 | $19 |
| Prochlorperazine Maleate | 14 | $247 | $18 |
| Sodium Chloride | 12 | $240 | $20 |
| Magnesium Sulfate | 15 | $88 | $6 |
| Folic Acid | 11 | $43 | $4 |
2021: 15 drugs
| Revlimid | 47 | $661,049 | $14,065 |
| Imbruvica | 27 | $437,268 | $16,195 |
| Xtandi | 25 | $309,292 | $12,372 |
| Eliquis | 26 | $13,082 | $503 |
| Hydroxyurea | 58 | $1,393 | $24 |
| Dexamethasone | 47 | $951 | $20 |
| Anastrozole | 22 | $603 | $27 |
| Prochlorperazine Maleate | 31 | $592 | $19 |
| Ondansetron Odt | 25 | $504 | $20 |
| Potassium Chloride | 26 | $291 | $11 |
| Bicalutamide | 14 | $242 | $17 |
| Methylprednisolone | 18 | $208 | $12 |
| Prednisone | 25 | $152 | $6 |
| Sodium Chloride | 12 | $128 | $11 |
| Allopurinol | 13 | $97 | $7 |
2020: 20 drugs
| Revlimid | 40 | $593,438 | $14,836 |
| Imbruvica | 20 | $335,629 | $16,781 |
| Xtandi | 22 | $255,661 | $11,621 |
| Piqray | 12 | $207,119 | $17,260 |
| Anagrelide | 14 | $2,920 | $209 |
| Hydroxyurea | 53 | $1,614 | $30 |
| Potassium Chloride | 15 | $847 | $56 |
| Dexamethasone | 35 | $819 | $23 |
| Anastrozole | 27 | $697 | $26 |
| Ondansetron Odt | 16 | $504 | $32 |
| Acyclovir | 34 | $438 | $13 |
| Prochlorperazine Maleate | 30 | $350 | $12 |
| Fluconazole | 12 | $334 | $28 |
| Bicalutamide | 12 | $178 | $15 |
| Sodium Chloride | 16 | $169 | $11 |
| Gabapentin | 15 | $135 | $9 |
| Allopurinol | 12 | $132 | $11 |
| Prednisone | 25 | $123 | $5 |
| Warfarin | 14 | $119 | $9 |
| Furosemide | 11 | $39 | $4 |
2019: 19 drugs
| Revlimid | 40 | $518,191 | $12,955 |
| Imbruvica | 13 | $245,763 | $18,905 |
| Ibrance | 12 | $152,048 | $12,671 |
| Verzenio | 12 | $149,970 | $12,497 |
| Promacta | 13 | $134,624 | $10,356 |
| Anagrelide | 15 | $1,764 | $118 |
| Hydroxyurea | 40 | $1,347 | $34 |
| Dexamethasone | 55 | $969 | $18 |
| Ondansetron Odt | 30 | $664 | $22 |
| Sodium Chloride | 38 | $527 | $14 |
| Warfarin | 24 | $516 | $22 |
| Anastrozole | 28 | $497 | $18 |
| Prochlorperazine Maleate | 39 | $384 | $10 |
| Bicalutamide | 22 | $311 | $14 |
| Letrozole | 20 | $224 | $11 |
| Methylprednisolone | 17 | $160 | $9 |
| Prednisone | 20 | $131 | $7 |
| Levofloxacin | 11 | $45 | $4 |
| Allopurinol | 11 | $22 | $2 |
2018: 24 drugs
| Revlimid | 22 | $318,564 | $14,480 |
| Imbruvica | 15 | $259,131 | $17,275 |
| Ibrance | 14 | $169,411 | $12,101 |
| Votrient | 12 | $120,490 | $10,041 |
| Exemestane | 11 | $2,996 | $272 |
| Hydroxyurea | 57 | $1,427 | $25 |
| Potassium Chloride | 22 | $1,277 | $58 |
| Dexamethasone | 34 | $608 | $18 |
| Anastrozole | 40 | $526 | $13 |
| Bicalutamide | 25 | $402 | $16 |
| Magnesium Sulfate | 27 | $399 | $15 |
| Ondansetron Odt | 18 | $397 | $22 |
| Klor-Con M20 | 17 | $395 | $23 |
| Letrozole | 33 | $371 | $11 |
| Prochlorperazine Maleate | 47 | $286 | $6 |
| Methylprednisolone | 18 | $262 | $15 |
| Warfarin | 27 | $234 | $9 |
| Sodium Chloride | 24 | $199 | $8 |
| Prednisone | 17 | $140 | $8 |
| Allopurinol | 19 | $109 | $6 |
| Gabapentin | 17 | $107 | $6 |
| Ciprofloxacin | 14 | $69 | $5 |
| Levofloxacin | 18 | $65 | $4 |
| Alendronate | 11 | $21 | $2 |
2017: 14 drugs
| Hydroxyurea | 35 | $968 | $28 |
| Tamoxifen Citrate | 14 | $725 | $52 |
| Klor-Con M20 | 18 | $643 | $36 |
| Ondansetron Odt | 20 | $494 | $25 |
| Potassium Chloride | 15 | $445 | $30 |
| Anastrozole | 33 | $426 | $13 |
| Dexamethasone | 26 | $360 | $14 |
| Methylprednisolone | 20 | $307 | $15 |
| Letrozole | 28 | $293 | $10 |
| Prochlorperazine Maleate | 36 | $188 | $5 |
| Allopurinol | 13 | $166 | $13 |
| Prednisone | 11 | $128 | $12 |
| Levofloxacin | 13 | $49 | $4 |
| Alendronate | 12 | $47 | $4 |
2016: 8 drugs
| Megestrol Acetate | 13 | $1,902 | $146 |
| Ondansetron Odt | 34 | $1,211 | $36 |
| Anastrozole | 36 | $719 | $20 |
| Hydroxyurea | 18 | $648 | $36 |
| Klor-Con M20 | 14 | $521 | $37 |
| Prochlorperazine Maleate | 51 | $462 | $9 |
| Methylprednisolone | 20 | $408 | $20 |
| Prednisone | 15 | $239 | $16 |
2015: 11 drugs
| Revlimid | 20 | $235,927 | $11,796 |
| Enoxaparin | 13 | $10,049 | $773 |
| Hydroxyurea | 26 | $1,011 | $39 |
| Anastrozole | 44 | $781 | $18 |
| Tamoxifen Citrate | 15 | $757 | $50 |
| Ondansetron Odt | 19 | $404 | $21 |
| Potassium Chloride | 11 | $373 | $34 |
| Klor-Con M20 | 11 | $368 | $33 |
| Dexamethasone | 14 | $362 | $26 |
| Prochlorperazine Maleate | 16 | $108 | $7 |
| Furosemide | 11 | $33 | $3 |
2014: 10 drugs
| Revlimid | 12 | $139,553 | $11,629 |
| Inlyta | 12 | $95,226 | $7,935 |
| Anastrozole | 64 | $2,141 | $33 |
| Potassium Chloride | 24 | $1,343 | $56 |
| Hydroxyurea | 31 | $1,243 | $40 |
| Tamoxifen Citrate | 32 | $1,091 | $34 |
| Hydrocodone-Acetaminophen | 15 | $1,035 | $69 |
| Levofloxacin | 28 | $745 | $27 |
| Ondansetron Odt | 20 | $604 | $30 |
| Prochlorperazine Maleate | 26 | $193 | $7 |
2013: 7 drugs
| Anastrozole | 63 | $2,400 | $38 |
| Hydroxyurea | 32 | $1,247 | $39 |
| Ondansetron Odt | 22 | $1,082 | $49 |
| Tamoxifen Citrate | 37 | $979 | $26 |
| Levofloxacin | 24 | $879 | $37 |
| Dexamethasone | 12 | $146 | $12 |
| Prochlorperazine Maleate | 17 | $117 | $7 |
Money from drug and device companies
$9,976 in 2025
| 2025 | 3 | 13 | $7,970 | $9,976 |
| 2024 | 4 | 15 | $12,860 | $13,804 |
| 2023 | 4 | 4 | $2,973 | $3,072 |
| 2022 | 7 | 24 | $14,131 | $15,896 |
| 2021 | 12 | 19 | $14,647 | $16,168 |
| 2020 | 6 | 10 | $4,505 | $5,050 |
| 2019 | 7 | 10 | $1,850 | $2,213 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Imfinzi | $6,600 | 8 payments
|
| Avyxa Pharma | None | $3,101 | 4 payments
|
| Cardinal Health 110 | None | $275 | 1 payment
|
See all 13 published payments
| AstraZeneca Pharmaceuticals LP | Travel · 2025-09-01 | Imfinzi | $149 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-01 | Imfinzi | $59 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-28 | Imfinzi | $3,015 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-07-19 | Imfinzi | $72 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-19 | Imfinzi | $38 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-07-19 | Imfinzi | $281 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-07-18 | Imfinzi | $306 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-07-14 | None | $2,680 |
| Avyxa Pharma | Meals · 2025-05-17 | None | $92 |
| Avyxa Pharma | Travel · 2025-05-17 | None | $415 |
| Avyxa Pharma | Travel · 2025-05-17 | None | $594 |
| Avyxa Pharma | Paid to speak or teach · 2025-05-17 | None | $2,000 |
| Cardinal Health 110 | Consulting · 2025-01-09 | None | $275 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $13,804
| AstraZeneca Pharmaceuticals LP | Imfinzi | $11,779 | 11 payments
|
| Avyxa Pharma | Docivyx | $1,000 | 1 payment
|
| BeiGene USA | Brukinsa | $825 | 2 payments
|
| Sobi | Vonjo | $200 | 1 payment
|
2023: $3,072
| AstraZeneca Pharmaceuticals LP | Enhertu | $1,943 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $830 | 1 payment
|
| Daiichi Sankyo | None | $200 | 1 payment
|
| Astellas Pharma US | None | $99 | 1 payment
|
2022: $15,896
| Incyte | Monjuvi | $7,493 | 16 payments
|
| CTI BioPharma | Vonjo | $3,000 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $1,943 | 1 payment
|
| Coherus Biosciences | None | $1,350 | 1 payment
|
| Novartis Pharmaceuticals | None | $1,275 | 1 payment
|
| BeiGene USA | Brukinsa | $635 | 2 payments
|
| Novocure GmbH | None | $200 | 1 payment
|
2021: $16,168
| Jazz Pharmaceuticals | Vyxeos | $3,885 | 1 payment
|
| Incyte | None | $3,373 | 8 payments
|
| Dova Pharmaceuticals | Doptelet | $3,040 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $1,943 | 1 payment
|
| Tg Therapeutics | None | $1,238 | 1 payment
|
| Blueprint Medicines | Ayvakit | $1,182 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $720 | 1 payment
|
| EMD Serono | Tepmetko | $500 | 1 payment
|
| Epizyme | Tazverik | $99 | 1 payment
|
| Astellas Pharma US | None | $95 | 1 payment
|
| Lilly USA | Cyramza | $82 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $5,050
| Jazz Pharmaceuticals | Vyxeos | $2,277 | 5 payments
|
| Incyte | None | $1,300 | 1 payment
|
| Celgene | Inrebic | $1,155 | 1 payment
|
| Athenex Pharmaceutical Division | None | $175 | 1 payment
|
| BeiGene USA | Brukinsa | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $18 | 1 payment
|
2019: $2,213
| Bayer HealthCare Pharmaceuticals | Aliqopa | $950 | 1 payment
|
| Genentech USA | Non-Covered Product | $856 | 2 payments
|
| Lilly USA | Verzenio | $115 | 3 payments
|
| Jazz Pharmaceuticals | Vyxeos | $113 | 1 payment
|
| Comsort | Keytruda | $100 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $62 | 1 payment
|
| Sirtex Medical | Sir-Spheres Microspheres | $18 | 1 payment
|
Checkups this office reported
4 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 82.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 98%That's most of the people this applied to. | 1,229 |
| Oncology: Medical and Radiation - Pain Intensity QuantifiedAs Medicare defines this measure | 98% | 373 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 97%That's most of the people this applied to. | 589 |
| Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life (lower score better)As Medicare defines this measure | 0% | 21 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Collects patient feedback
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Reports cases to public health electronically
- Reports immunizations to the state registry
- Reports to a public-health or clinical registry
Professional record
- NPI
- 1033284823
- Licence
- NY 180765
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- NY 01605912
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 69 Prospect Ave, Hudson, NY, 12534
- NPI first listed
- 2006-11-21
- NPI last updated
- 2019-03-19
This is when the NPI record was last certified, not a medical board exam.